Atlas Trials

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Clinical trial NCT04405505 · UNKNOWN

Trial details

NCT number
NCT04405505
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2020-06-01
Primary completion
2022-07-01
Enrollment
332

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.